Slide 1: Future Proof Healthcare - Presentation Q2(23)
FUTURE PROOF HEALTHCARE A sustainable healthcare for a new generation Presentation Q2(23) Jonas Jarvius, CEO Christer Samuelsson, CFO/IR
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 2nd quarter
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 2nd quarter Q-linea is developing disruptive solutions for faster infectious disease diagnostics, first product targeting sepsis Introduction to the company Lead product ASTar® Implementation of new commercialisation stra
Slide 4: Q-linea 2nd quarter: rights issue
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 2nd quarter Q-linea is developing disruptive solutions for faster infectious disease diagnostics, first product targeting sepsis Introduction to the company Lead product ASTar® Announced a rights issue 1st June, Approved
Slide 5: Q-linea 2nd quarter: cost savings program
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 2nd quarter Q-linea is developing disruptive solutions for faster infectious disease diagnostics, first product targeting sepsis Introduction to the company Lead product ASTar® Cost savings program accomplished Enable foc
Slide 6: A summary of events in the 2nd quarter 2023
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 2nd quarter A summary of events in the 2nd quarter 2023 April Introduction to the company 3rd Q-linea receives orders for two ASTar instruments from Pro-Lab 4th Q-linea signs distribution partnership with Integra Diagnost
Slide 7: A summary of events after the 2nd quarter 2023
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 2nd quarter A summary of events after the 2nd quarter 2023 July Introduction to the company 4th Q-linea announced that Franco Pellegrini has been appointed as Sales Director for Southern Europe at Q-linea. 6th Q-linea ann
Slide 8: Strengthening of the board
Strengthening of the board Finn Sander Albrechtsen has more than 16 years of international leadership experience from the life science and diagnostics industry. This includes seven years with Dako and Agilent Technologies in positions focused on product development, from portfolio- and project manag
Slide 9: Strengthening of the commercial team in Italy & USA
Strengthening of the commercial team in Italy & USA Franco Pellegrini James Kathrein, General Manager Italy and Southern VP of US Commercial Operations European Sales Director Franco has had senior roles in the Jim has held senior commercial roles Microbiology division of Thermo Fisher in several pr
Slide 10: Time to actionable results is important
Time to actionable results is important Sepsis is the most common cause of death in our hospitals More common than lung + prostate + breast-cancer combined Accounts for approximate 30% of all deaths in the hospital Most expensive condition to treat in the US. >27B USD1) Time to correct treatment is
Slide 11: Rapid AST & a broad antimicrobial panel matters
Rapid AST & a broad antimicrobial panel matters: ASTar can provide up to 48 hours faster actionable results Transportation of blood culture from patient to laboratory: 1 – 24+ hours DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood dra
Slide 12: ASTar performance is strong and it is easy to use
ASTar performance is strong and it is easy to use Evaluation of commercial systems for rapid antimicrobial susceptibility testing (rAST) of positive blood cultures: Comparison of susceptibility results View Sheffield Hospital’s scientific poster presentation from ECCMID 2022, featuring the ASTar Sys
Slide 13: Tentative market for rAST from blood cultures in 2025
Tentative market for rAST from blood cultures in 2025 If one assumes that rAST is important for patients with Sepsis Sepsis Positive blood cultures 1) Assume 20% eligible for If equally divided by selected2) 20 M testing with rAST 1) current rAST providers 4 M test 1 M test Key: Primary markets Othe
Slide 14: Focus on executing our updated Go-to-Market strategy
Focus on executing our updated Go-to-Market strategy Key activities to support sales • Conferences and Tradeshows • Service and Support capabilities • Responding to tenders • HEOR studies • Customer evaluation studies • Distribution Partners agreements
Slide 15: Health Economic and Outcomes Research (HEOR)
Health Economic and Outcomes Research (HEOR) First patient enrolled in the Italian multicentre Lifetimes HEOR study Q-linea sponsored multicentre study investigating the health and economic benefits of using ASTar when treating ICU patients with bloodstream infections. The study will enroll 160 pros
Slide 16: Updated commercialisation strategy – summary so far
Updated commercialisation strategy – summary so far During 2023, we have significantly increased commercial footprint in Europe and have started in the USA Goal is to demonstrate ASTar commercially & Enable a strong ramp-up in 2024 16 Source: Company information 16
Slide 17: ASTar in focus but with unique disruptive expansion pipeline
ASTar in focus but with unique disruptive expansion pipeline & opportunities Product 1 to 3 years 3 to 5 years On market ASTar® Extended panels Expansion Expansion Expansion CE IVD & Isolates Urine other indications and BC G- capabilities in development Podler® Clinical studies Commercial EU/US laun
Slide 18: Consolidated statement of profit and loss - second quarter
Consolidated statement of profit and loss - second quarter Net sales in the second quarter amounted to SEK 1.4 million (4.1). Operating result totalled SEK -64.6 million (-72.7). The company reported a loss after tax of SEK -65.0 million (-73.2). Earnings per share, before and after dilution amounte
Slide 19: Consolidated statement of financial position - end of second quarter
Consolidated statement of financial position - end of second quarter Cash and cash equivalents amounted to SEK 25.0 million (72.9). Inventories amounted to SEK 45.6 million (42.3). Equity amounted to SEK 32.9 million (163.2) Loan from principal owner SEK 87.0 million (0) Source: Company information.
Slide 20: Cash flow statement second quarter
Cash flow statement second quarter Cash flow from operating activities SEK -53.5 million (-64.5). Decrease in cash outflow from operating activities mainly due to favourable changes in the working capital compared to the same quarter last year. Cash flow from investing activities SEK -2.4 million (7